U.S. markets closed

Cyclacel Pharmaceuticals, Inc. (CYCCP)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
8.24+0.24 (+3.00%)
At close: 12:45PM EDT
Sign in to post a message.
  • S
    *Cyclacel Pharmaceuticals shares are trading higher after Oppenheimer initiated coverage on the stock with an Outperform rating and a $17 price target.
  • P
    Short position continues to decline---down 11% last month. They want your stock cheap---don't give it to them'
  • G
    Grizzly Adams
    Why was the cover rating so high
    1k shares added today
  • d
    PT $ 17....let's join the party
  • p
    Are these guys crazy ? I just read the proxy vote items and after a reverse split and drop from $31 to $7 the want you to vote to create more shares and ceo compensation????
  • I
    Same ole, same ole.. post quarterly reports. Be sure to read Matt's post below. He nailed it.
  • M
    In the past after a dilution, it is followed by short selling, stock price decline over 3 to 4 years and a reverse split. For all longs sake, I hope it is different this time. Good luck to you.
  • O
    Spiro and Paul doing what they have been doing best for the past 2 decades...1)never getting an approved oncology molecule successful thorough clinical trials and 2)diluting out the share holders. oh and I almost forgot......reverse splits! Did I miss anything?
  • G
    Don't worry People "Spiro the Zero", will take care of you.
  • T
    Ok listen up... this is shorted 51% of float and its cheap start buying (like reddit) and shorts will have to cover then it will spike!!! Go on finviz click scanner find stks short 30%+ under $30 usa do same
  • D
    Wow. Better than I expected really. No dilution for a while or at least not 2 days after er. Also a lot going on this year that could be good. Low volume. Down this much? Time to turn the tide on this me thinks
  • D
    I’ll help but we can’t let this close under 7. There won’t be any reverse split. No need too. Plenty of cash through 2023. No dilution to worry about. This should be higher but big money is calling the shots. Rage against the machine!!!
  • K
    I've had a small stake in this based on some of the early stage drug candidates, including (or perhaps especially) 065. When they initially reported a response with 065, was hoping this would be followed by more promising data. Esmo came and went with no promise fulfilled. But I've kept a small stake here to see what happens next. Today's events, coupled with the board appointment, make clear that 140 is now the golden child with the potential to make CYCC a BO target, similar to what happened with ARQL (which I owned from the 3's before we were bought by Merk for 20).
  • N
    according to ClinicalTrials.gov, the company’s CDK Inhibitor and Venetoclax study in relapsed or refractory CLL patients is expected to be completed by this Friday, May 15, 2020. This is important to keep in mind as not only did the company have great operational results, there’s likely a catalyst ahead as we hear more about this trial.
  • A
    My first stock purchase was CYCC when it was about $4.80 years ago. I bought about 950 shares. Then...a 12-1 stock split May 2016, then another split of 20-1 this month. I now have 4 shares. I only need it to go to $1,140 to break even...$1,277 to go! Yeah...and I love paper cuts too.
  • G
    Real, you're correct. CYCC deserves a following, so I'll jump in. Based on my risk/reward analysis, I'm a long term holder for a myriad of reasons. On a shorter term basis, the most exciting program may be the kids neuroblastoma trial, which will be run as an IST. An arm of the UK will be running the trial. COVID -19 has caused delays to the start during 2020 so even though it was recently projected to open enrollment about now, it won't be a surprise if it gets delayed for awhile longer. The pre clinical results were truly eye catching. Fadraciclib (aka CYC065) is being used as a single agent in the trial. Once the trial begins, hopefully the company will give a timeline for enrollment and completion. My guess, within 1 1/2 years, if not less.
  • K
    New form 13G filed by Pura Vida Investments; bought 475K shares at 6.40/share.
  • P
    Selling has dried up here on diminishing volume and it looks like we should get a nice pop here. With $5.21 cash per share, no debt, and a pipeline getting closer to fruition---any good news re clinicals or possible takeover interest could send this a lot higher. My opinion.
  • D
    Here goes the short. If it isn’t a picture perfect quarter or some really good new the people who are shorting will take this down under 4. Seeing another dilution and reverse stock split coming only because the shorts drove the price down so much. Terrible situation
  • C
    in @4.25 . price target of $130. all you need to know. going to load on dips but this will probably be at $5 come monday morning